

VIVORYON THERAPEUTICS AG

ISIN: NL00150002Q7 WKN: - Asset Class: Stock

Company

2024/04/26 17:35:27



Price

0.80 EUR

Difference ▼ -2.44% (-0.02)



Contact Details

VIVORYON THERAPEUTICS NV

Tel: +49-345-555-99-00

--

Fax: +49-345-555-99-01

Weinbergweg 22

Web:

<http://www.vivoryon.com>

06120 Halle

E-mail: info@vivoryon.com

Company Profile

Vivoryon Therapeutics NV is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its product pipeline includes PQ912, PBD-C06, and PQ1565. The company was founded by Hans-Ulrich Demuth and Konrad Glund on July 25, 1997 and is headquartered in Halle, Germany.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	29,812,000		30,694,000		20,229,000	
Common stock capital		26,067,000		24,105,000		20,050,000
Fixed assets	1,017,000		684,000		4,291,000	
Equity capital of a company		26,282,000		26,506,000		16,557,000
Cash and cash equivalents	18,562,000		26,555,000		14,661,000	
Accrued liabilities		1,365,000		1,335,000		1,835,000
Other assets	-		-		-	
Current liabilities		3,182,000		3,265,000		5,051,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		1,365,000		1,607,000		2,912,000
Different income		-		-		-
Other liabilities		0		0		513,000
Total assets	30,829,000	30,829,000	31,378,000	31,378,000	24,520,000	24,520,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	-	17	17
Equity ratio	85.25%	84.47%	67.52%
Debt-equity ratio	17.30%	18.38%	48.09%

Others

	2023	2022	2021
Tax Expense Rate	-%	0.70%	-3.53%

VIVORYON THERAPEUTICS AG

ISIN: NL00150002Q7 WKN: - Asset Class: **Stock**

Income statement

	2023	2022	2021
Turnover	-3,620,000	0	10,764,000
Net income	-28,342,000	-28,156,000	-12,655,000
EBIT	-28,576,000	-28,373,000	-12,220,000
Operating income before taxes	-28,576,000	-28,355,000	-12,223,000
Cash Flow	-21,541,000	-21,794,000	-11,257,000
Net interest income	261,000	18,000	-3,000
Research and development expenses	17,637,000	20,224,000	17,452,000
Income taxes	-234,000	-199,000	432,000
Result from investments in subsidiaries, associates and other	-	0	0
Revenues per employee	-	0	633,176

Board of Directors

Erich Maximilian Platzer	Chairman of Supervisory Board
Claudia Riedi	Member of Supervisory Board
Michael Schaeffer	Member of Supervisory Board
Samir Shah	Member of Supervisory Board
Anne Doering	Member of Supervisory Board
Charlotte Lohmann	Member of Supervisory Board

Members of Management Board

Frank Weber	Chairman of Managing Board
Michael Schaeffer	Member of Executive Committee
Anne Doering	Member of Executive Committee
Florian Schmid	Member of Executive Committee